Literature DB >> 25795783

Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in β-Thalassemia Induced Pluripotent Stem Cells (iPSCs).

Ning Ma1, Yongli Shan1, Baojian Liao1, Guanyi Kong2, Cheng Wang2, Ke Huang1, Hui Zhang1, Xiujuan Cai1, Shubin Chen1, Duanqing Pei1, Nansheng Chen3, Guangjin Pan4.   

Abstract

The generation of personalized induced pluripotent stem cells (iPSCs) followed by targeted genome editing provides an opportunity for developing customized effective cellular therapies for genetic disorders. However, it is critical to ascertain whether edited iPSCs harbor unfavorable genomic variations before their clinical application. To examine the mutation status of the edited iPSC genome and trace the origin of possible mutations at different steps, we have generated virus-free iPSCs from amniotic cells carrying homozygous point mutations in β-hemoglobin gene (HBB) that cause severe β-thalassemia (β-Thal), corrected the mutations in both HBB alleles by zinc finger nuclease-aided gene targeting, and obtained the final HBB gene-corrected iPSCs by excising the exogenous drug resistance gene with Cre recombinase. Through comparative genomic hybridization and whole-exome sequencing, we uncovered seven copy number variations, five small insertions/deletions, and 64 single nucleotide variations (SNVs) in β-Thal iPSCs before the gene targeting step and found a single small copy number variation, 19 insertions/deletions, and 340 single nucleotide variations in the final gene-corrected β-Thal iPSCs. Our data revealed that substantial but different genomic variations occurred at factor-induced somatic cell reprogramming and zinc finger nuclease-aided gene targeting steps, suggesting that stringent genomic monitoring and selection are needed both at the time of iPSC derivation and after gene targeting.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Gene Therapy; Genomic Instability; Genomics; Induced Pluripotent Stem Cell (iPS Cell) (iPSC); Reprogramming

Mesh:

Substances:

Year:  2015        PMID: 25795783      PMCID: PMC4424344          DOI: 10.1074/jbc.M114.624999

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice.

Authors:  Yixuan Wang; Chen-Guang Zheng; Yonghua Jiang; Jiqin Zhang; Jiayu Chen; Chao Yao; Qingguo Zhao; Sheng Liu; Ke Chen; Juan Du; Ze Yang; Shaorong Gao
Journal:  Cell Res       Date:  2012-02-07       Impact factor: 25.617

2.  Copy number variation and selection during reprogramming to pluripotency.

Authors:  Samer M Hussein; Nizar N Batada; Sanna Vuoristo; Reagan W Ching; Reija Autio; Elisa Närvä; Siemon Ng; Michel Sourour; Riikka Hämäläinen; Cia Olsson; Karolina Lundin; Milla Mikkola; Ras Trokovic; Michael Peitz; Oliver Brüstle; David P Bazett-Jones; Kari Alitalo; Riitta Lahesmaa; Andras Nagy; Timo Otonkoski
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

3.  Detection and quantification of rare mutations with massively parallel sequencing.

Authors:  Isaac Kinde; Jian Wu; Nick Papadopoulos; Kenneth W Kinzler; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-17       Impact factor: 11.205

4.  Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression.

Authors:  Linzhao Cheng; Nancy F Hansen; Ling Zhao; Yutao Du; Chunlin Zou; Frank X Donovan; Bin-Kuan Chou; Guangyu Zhou; Shijie Li; Sarah N Dowey; Zhaohui Ye; Settara C Chandrasekharappa; Huanming Yang; James C Mullikin; P Paul Liu
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

Review 5.  Thalassemias.

Authors:  Alissa Martin; Alexis A Thompson
Journal:  Pediatr Clin North Am       Date:  2013-10-04       Impact factor: 3.278

6.  Multiplex genome engineering using CRISPR/Cas systems.

Authors:  Le Cong; F Ann Ran; David Cox; Shuailiang Lin; Robert Barretto; Naomi Habib; Patrick D Hsu; Xuebing Wu; Wenyan Jiang; Luciano A Marraffini; Feng Zhang
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

7.  Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell differentiation cultures.

Authors:  Kyung-Dal Choi; Maxim A Vodyanik; Padma Priya Togarrati; Kran Suknuntha; Akhilesh Kumar; Fnu Samarjeet; Mitchell D Probasco; Shulan Tian; Ron Stewart; James A Thomson; Igor I Slukvin
Journal:  Cell Rep       Date:  2012-09-13       Impact factor: 9.423

Review 8.  Genetic and epigenetic variations in iPSCs: potential causes and implications for application.

Authors:  Gaoyang Liang; Yi Zhang
Journal:  Cell Stem Cell       Date:  2013-08-01       Impact factor: 24.633

9.  Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells.

Authors:  Alexej Abyzov; Jessica Mariani; Dean Palejev; Ying Zhang; Michael Seamus Haney; Livia Tomasini; Anthony F Ferrandino; Lior A Rosenberg Belmaker; Anna Szekely; Michael Wilson; Arif Kocabas; Nathaniel E Calixto; Elena L Grigorenko; Anita Huttner; Katarzyna Chawarska; Sherman Weissman; Alexander Eckehart Urban; Mark Gerstein; Flora M Vaccarino
Journal:  Nature       Date:  2012-11-18       Impact factor: 49.962

10.  Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells.

Authors:  Yanting Xue; Xiujuan Cai; Linli Wang; Baojian Liao; Hui Zhang; Yongli Shan; Qianyu Chen; Tiancheng Zhou; Xirui Li; Jundi Hou; Shubin Chen; Rongping Luo; Dajiang Qin; Duanqing Pei; Guangjin Pan
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more
  17 in total

Review 1.  Current Progress in Therapeutic Gene Editing for Monogenic Diseases.

Authors:  Versha Prakash; Marc Moore; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2016-01-14       Impact factor: 11.454

2.  Ground state naïve pluripotent stem cells and CRISPR/Cas9 gene correction for β-thalassemia.

Authors:  Alessia Finotti; Monica Borgatti; Roberto Gambari
Journal:  Stem Cell Investig       Date:  2016-10-25

Review 3.  Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy.

Authors:  Alok Srivastava; Ramachandran V Shaji
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

4.  Influence of ATM-Mediated DNA Damage Response on Genomic Variation in Human Induced Pluripotent Stem Cells.

Authors:  Junjie Lu; Hu Li; Anna Baccei; Takayo Sasaki; David M Gilbert; Paul H Lerou
Journal:  Stem Cells Dev       Date:  2016-04-11       Impact factor: 3.272

5.  CD34+ cells from dental pulp stem cells with a ZFN-mediated and homology-driven repair-mediated locus-specific knock-in of an artificial β-globin gene.

Authors:  S Chattong; O Ruangwattanasuk; W Yindeedej; A Setpakdee; K Manotham
Journal:  Gene Ther       Date:  2017-05-22       Impact factor: 5.250

Review 6.  Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells.

Authors:  Alison E Mungenast; Sandra Siegert; Li-Huei Tsai
Journal:  Mol Cell Neurosci       Date:  2015-12-04       Impact factor: 4.314

7.  CRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells.

Authors:  Xie Yingjun; Xie Yuhuan; Chen Yuchang; Li Dongzhi; Wang Ding; Song Bing; Yang Yi; Lu Dian; Xue Yanting; Xiong Zeyu; Liu Nengqing; Chen Diyu; Sun Xiaofang
Journal:  Ann Hematol       Date:  2019-09-09       Impact factor: 3.673

Review 8.  Gene correction in patient-specific iPSCs for therapy development and disease modeling.

Authors:  Yoon-Young Jang; Zhaohui Ye
Journal:  Hum Genet       Date:  2016-06-02       Impact factor: 4.132

9.  Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.

Authors:  Ning Ma; Joe Z Zhang; Ilanit Itzhaki; Sophia L Zhang; Haodong Chen; Francois Haddad; Tomoya Kitani; Kitchener D Wilson; Lei Tian; Rajani Shrestha; Haodi Wu; Chi Keung Lam; Nazish Sayed; Joseph C Wu
Journal:  Circulation       Date:  2018-12-04       Impact factor: 29.690

10.  Gene therapy for hemoglobin disorders - a mini-review.

Authors:  Parul Rai; Punam Malik
Journal:  J Rare Dis Res Treat       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.